Drugs, containing cyclosporine, in the form of capsules, soft coated

 

(57) Abstract:

The invention can be used in pharmacy and medicine to suppress innate immunological responses of a living organism, the cause of which is the transplantation of tissues and organs. Offered product in the form of gelatin capsules, soft coated. The capsule contains a pharmaceutical composition comprising: I - cyclosporine, II - propylene carbonate, III - a mixture of triglycerides of fatty acids with medium chain length and monoglyceride fatty acids as lubricant and IV - surface-active substance is hydrophilic-lipophilic balance (LB) which ranges from 8 to 17. The invention allows to create a dosage form having a standard dose of cyclosporine, convenient for administration to the patient. Pharmaceutical composition in the capsule is stable and has a high biological availability, regardless of the characteristics of individual patients. 15 C.p. f-crystals, 4 PL.

The invention relates to the preparation, for example, in the form of capsules, soft coated, containing as the active ingredient, ciclosporin. In particular the present invention relates to the preparation in the form of capsules, soft coated, containing Stavrogin specific plasticizer, and to its method of preparation.

Cyclosporine is a known macromolecular (molecular weight 1202,64) cyclic peptide compound consisting of 11 amino acids and has a wide range of useful pharmacological properties, in particular immunosuppressive activity and anti-inflammatory action. Consequently, cyclosporine is used to suppress innate immunological responses of a living organism, the cause of which is the transplantation of tissues and organs, such as heart transplantation, lung, liver, kidney, pancreas, bone marrow, skin and cornea, and primarily transplantation alien tissues and organs. In addition, cyclosporine is used in the treatment of hematological disorders such as anemia, various autoimmune diseases such as systemic lupus erythematosus, idiopathic malabsorption syndrome, and so on, and inflammatory diseases such as arthritis, rheumatoid disorders, etc. Cyclosporine is used in the treatment of diseases caused by protozoa such as malaria, schistosomiasis, and so on, and, in addition, he currently is also used in chemotherapy.

Cyclosporine is Visocolor is in organic solvents, such as methanol, ethanol, acetone, simple, ether, chloroform, etc., Because, as stated above, cyclosporine has a low solubility in water, in the case when cyclosporine is administered orally, its bioavailability is very low, and it can largely depend on the characteristics of each individual patient. As a result, it is difficult to maintain effective therapeutic against concentration. Moreover, cyclosporine can have strong side effects, such as nephrotoxicity. Due to the low solubility of cyclosporin in water is very difficult to produce on the basis of preparations for oral administration. Therefore, we carried out extensive, numerous studies aimed at the development of a drug that would be suitable for the effective introduction of cyclosporine oral route and which could provide an acceptable standard dose and appropriate bioavailability.

Known preparations suitable for oral administration of poorly water cyclosporine, usually produced in the form of pre-prepared emulsion concentrate.

One of the Ana liquid composition on the basis of cyclosporine with ethanol. In accordance with the method according to this U.S. patent, to obtain a liquid composition cyclosporine combined with a carrier consisting of ethanol as a secondary surfactant; olive oil as the vegetable oil and the product of the interesterification of triglycerides of natural vegetable oils and polyalkyleneglycol as surface-active substances.

However, the resulting liquid composition is injected into the aqueous solution, which is very difficult to adapt to its introduction and establishment of standard doses for oral administration.

To reduce the inconvenience associated with the dissolution liquid compositions on the basis of cyclosporine in the water before oral introduction, the liquid composition in the form of pre-prepared emulsion concentrate was made in the preparation of capsules with soft coating, which is currently commercially available and known as Sandimmune (registered trademark). In this case, the composition containing cyclosporine capsules, soft coated include ethanol, due to the requirements related to the solubility of cyclosporine. However, since ethanol due to its volatility can penetrate through the preparations in the form of capsules with a soft covering for storage and sale of drugs in the form of capsules, soft coated can be enclosed in a shell made of special packaging material, for example blister packaging aluminum-aluminum.

Recently it has become possible to create a drug on the basis of cyclosporine, which is stable throughout the intended shelf life, and further retains its biological availability, which does not depend on the individual characteristics of individual patients, so the biological effect of cyclosporine can be maintained at the same level. One of the drugs developed for this purpose, is described in published lined Korean patent 93-113. This drug is sold under the trademark Sandimmun Neoral. However, because this drug is also used ethanol, it may have some drawbacks in terms of stability during storage associated with changes in ethanol content and characteristic of the known preparations containing ethanol.

Therefore, when creating the present invention examined a large number of combinations of various surfactants, sizing, secondary surfactants, etc. with the purpose to find the song on the basis of cyclosporine, which is stable from the point of view of their pharmacokinetic characteristics the Sith from individual to individual patients in comparison with the known compounds based on cyclosporine. In the result it was found that a composition based on cyclosporine, consisting of the following components that can satisfy the above requirements, which was the object of the present invention.

Therefore, the present invention was based on the task to create a suitable for introduction into capsules with a soft coating composition containing cyclosporin as an active ingredient, a hydrophilic substance is polyethylene glycol or nigerienne substance propylene carbonate or a mixture thereof, sizing, as defined below, and surfactant.

Another object of the invention is the development of a drug in the form of capsules with a soft coating that contains a composition that includes a cyclosporin as active ingredient, a hydrophilic substance is polyethylene glycol or nigerienne substance propylene carbonate or a mixture, the mixture is esterified compounds of fatty acid and primary alcohol, triglyceride fatty acids with medium chain length (if necessary) and monoglyceride fatty acids as lubricant and surfactant, the HLB value (hydrophilic-lipophilic balance) which is placed above the product in the form of capsules, soft gelatin coating, as specified above.

Although this invention is described capsules soft gelatin coating, it is obvious that the invention includes the composition itself, which can be used, for example, in the form of a solution for drinking, for example, as Sandimmun Neoral, or other conventional dosage forms.

According to the present invention is proposed containing cyclosporine capsule, which has a high storage stability, i.e., it is characterized by a slight change in composition over time, and which has a high bioavailability and contains a composition comprising a cyclosporin as active ingredient, a hydrophilic substance is polyethylene glycol or nigerienne substance propylene carbonate or a mixture thereof as a second component, the sizing, as defined below, and surfactant.

For the manufacture of such a product in the form of capsules with soft coating containing composition on the basis of cyclosporine, it is necessary to use a gelatin shell. However, if the capsule with a soft coating is manufactured using a conventional capsule shell containing as plasticizer pinost pre-prepared emulsion concentrate may be altered due to the penetration of glycerol into the emulsion, that leads to a significant decrease in the solubility of cyclosporine and, as a consequence, the deposition of cyclosporine from the emulsion.

Therefore, in the present invention to shell capsules, soft coated preferably choose the gelatinous shell, in which the plasticizer is a mixture of polypropylenglycol and polyethylene glycol, but not glycerol, which allows to solve the problem of penetration of glycerol.

However, if the tape shells of capsules containing in accordance with the present invention the propylene glycol and polyethylene glycol, are made using the method of water cooling, which is usually used for drum refrigerators, it is difficult to remove from the drum. This feature extracted tape shells of capsules from the drum of the refrigerator can be improved by cooling drum fridge with continuous circulation of cooling water to reduce the temperature of the tape to approximately 17oC. However, the tape shells of capsules, cooled to a lower temperature, may have a reduced ability to hermetic sealed in the encapsulation process, which may lead to decrease in production is este plasticizer glycerin, instead of the previously known method of water cooling in accordance with the present invention uses a method of air cooling, whereby the tape shells of capsules can be cooled to an optimum temperature by means of air flow from the fan and could therefore be easily removed from the drum fridge with subsequent keeping the tape at the optimum temperature of approximately 21oWith to improve the ability hermetically sealed in the encapsulation process, which ensures high performance.

As indicated above, the products of the present invention can be manufactured using does not contain glycerin gelatin shell of the capsule and using the method of air cooling composition that does not contain ethanol, which is a solvent with a low boiling point, and therefore, has high storage stability, i.e., the composition varies little over time and is characterized by high biological availability.

In particular, according to the invention is proposed based drug cyclosporine containing composition, which includes

1) qi/BR> 3) a mixture of esterified compounds of fatty acid and primary alcohol and monoglyceride fatty acid and optionally a triglyceride of fatty acids with medium chain length as lubricant and

4) surfactant, the HLB value (hydrophilic-lipophilic balance) of which is from 8 to 17,

and which, for example, is enclosed in a gelatin shell containing as plasticizer polyethylene glycol and propylene glycol. Further, according to the invention is proposed based drug cyclosporine containing composition, which includes

1) a cyclosporin as active ingredient and

2) propylene carbonate.

This composition, which is also a composition according to the invention can optionally further comprise any other component presented in the present description, in the amounts, specified in the present description.

Cyclosporine, which is used as a pharmaceutically active ingredient proposed composition, is a cyclic peptide compounds having immunosuppressive activity and anti-inflammatory action, as described above. Although as cyclosporines most preferred because of its clinical efficacy and pharmacological properties, well known in this field.

As a hydrophilic substance, which is the second component in the proposed composition, it is possible to use polyethylene, which may function as a secondary surfactant has a high boiling point, is non-volatile, does not penetrate through the gelatinous shell capsules, soft coated, and in which soluble cyclosporine. Although the composition of the present invention can be applied to any polyethylene glycol, which may be liquefied, it is preferable to use polyethylene glycol (PEG) having a molecular weight of from 200 to 600, in particular PEG 200.

Alternatively, as negidrirovannogo component can also be applied propylene carbonate (tKipapproximately 242oC). According to the invention can also be applied mixture negidrirovannogo substance and a hydrophilic substance, as defined above. When as a component of the present invention using a mixture of polyethylene glycol and propylene carbonate, they can usually be combined in a mass ratio of 1:0.1 to 5, preferably 1:0.1 to 3, most preferably 1:0.2 to 2.

The use of polyethylene is substance. So, for example, improves the storage stability of the composition containing cyclosporine, and therefore, practically at a constant level supported by the content of its components. In addition, the use of propylene carbonate can even increase the solubility of an active ingredient of cyclosporine and to inhibit the penetration of water from the gelatin shell of the capsule in the composition, making the composition more stable.

In the composition of the present invention the second component is preferably used in a ratio of from 0.1 to 10 mass parts, more preferably from 0.5 to 8 mass parts, and most preferably from 1 to 5 mass parts per 1 mass part of cyclosporine.

The third component used in the previously prepared emulsion concentrate according to the present invention is the sizing. As lubricant according to the invention can be applied to the mixture of esterified compounds of fatty acid and primary alcohol, triglyceride (when they are present) fatty acids with medium chain length and monoglycerides of fatty acids. Esterified compound of fatty acid and primary alcohol, which can be used is s carbon and a primary alcohol having 2-3 carbon atoms, such as isopropylmyristate, isopropyl, ethyllinoleate, etiloleat and so on, and particularly preferred is esterified compound of linoleic acid and ethanol. In addition, as the triglyceride (when present) fatty acids with medium chain length can be used triglyceride of saturated fatty acids having 8-10 carbon atoms, and most preferred triglyceride of saturated fatty acid from entering into the composition of vegetable oil is a triglyceride Caprylic/capric acid. The monoglyceride of a fatty acid, which can also be used as lubricant of the present invention, includes a monoglyceride of a fatty acid having from 18 to 20 carbon atoms, in particular the monoglyceride of oleic acid.

In a pre-prepared microemulsion concentrate according to the present invention, the lubricant can be applied in a ratio of from 1 to 10 mass parts, preferably from 2 to 6 mass parts per 1 mass part of cyclosporine.

Preferably as lubricant contains a monoglyceride of a fatty acid and a fatty acid ester, for example, in shootability/capric acid, for example, in relation to ethyllinoleate from 1:0.1 to 1:0,2.

In the mixture of oils used as lubricant of the present invention, the mass ratio of the monoglyceride of fatty acid esterified compound of fatty acid and primary alcohol/triglyceride (when present) fatty acids with medium chain length can typically be in the range from 1:0.1 to 5:0.1 to 10, preferably from 1:0.1 to 3,0:0,1-3,0.

The fourth component used in the compositions of the present invention is a surfactant. Acceptable for use in the present invention, surfactants are any pharmaceutically acceptable surfactants, the HLB value (hydrophilic-lipophilic balance) ranging from 8 to 17 and which can stably emulsify lipophilic part of the composition comprising a lubricant containing cyclosporine, and a hydrophilic part, including secondary surfactant in water, which leads to the formation of stable micro-emulsions. Examples of preferred surfactants of the present invention include polyoxyethylene products hereroland the IKKOL VAT-40, NIKKOL HCO-60, TWEEN 20, TWEEN 21, TWEEN 40, TWEEN 60, TWEEN 80, TWEEN 81, etc., In particular, can preferably be used polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links that sold under the trade name NIKKOL HCO-50, NIKKO Chemical Co. Co., Ltd.) and polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links that sold under the trade name TWEEN 20 (firm ICI Chemicals), having an acid number below 1, a saponification number of approximately 48-56, a hydroxyl number of approximately 45-55 and pH (5% solution) 4,5-7,0.

Surfactant can be either any one of the above surfactants, or preferably a combination of two or more surfactants selected from the above-mentioned surfactants. In the composition according to the present invention, surfactants can be used in a ratio of from 1 to 10 mass parts, preferably in the ratio from 2 to 8 mass parts per 1 mass part of cyclosporine.

In addition, when the composition of the present invention using a mixture of two surfactants, i.e. polietilenovogo of sorbitanoleat, containing 20 moles ethyleneoxide links made mass ratio polyoxyethylene hydrogenated castor oil containing 50 moles ethyleneoxide links, and polyoxyethylene of sorbitanoleat containing 20 moles ethyleneoxide units, is preferably 1:0.1 to 5, more preferably 1:0.5 to 4.

In the composition of the present invention four components cyclosporine/ second component/ lubricant/ surfactant is preferably present in a weight ratio of 1:0,1-10:1-10:1-10, more preferably in a ratio of 1:0,5-8:2-6:2-8.

In addition to this composition as an additional preferred compositions of the present invention may be noted the composition shown in the following examples.

For oral administration composition of the present invention, containing the above components can be manufactured in the form of capsules with soft coating. Because the drug is in the form of capsules, soft coated in accordance with the present invention is not used ethanol as a volatile solvent with a low boiling point, this drug is a pharmaceutically stable and can udovletvor may be, that this goal is difficult to achieve using conventional shell capsules, soft coated using a conventional method of manufacturing capsules with soft coating. When they produce a capsule, soft coated using conventional capsule shell containing as plasticizer glycerin produced thereby capsule with a soft coating may have a number of disadvantages, namely that the stability of the previously prepared emulsion concentrate may be altered due to the penetration of glycerol into the emulsion and, as a consequence, a significant decrease in the solubility of cyclosporine, which can lead to the deposition of cyclosporine from the emulsion.

Thus, it was found that, when the shell of a capsule made, using as a plasticizer mixture of polyethylene glycol and propylene glycol, but not glycerol, the resulting product in the form of capsules with a soft coating is stable over a long period of time, which in turn is yet another object of the present invention. Although the plasticizer may be any polyethylene glycol, which may be liquefied, preferably used is SQL polyethylene glycol 200. Shell capsules, soft coated in accordance with the present invention, a mixture of polyethylene glycol and propylene glycol, preferably in a ratio of from 0.1 to 0.5 mass parts, more preferably from 0.1 to 0.4 mass parts, and most preferably from 0.2 to 0.3 mass parts of one mass part of the gelatin used to manufacture the shell of the capsule. Used as a plasticizer mixture of polyethylene glycol and propylene glycol latter of which is preferably in the ratio from 1 to 10 mass parts, more preferably 3 to 8 mass parts, and most preferably from 3 to 6 mass parts of one mass part of polyethylene glycol.

To improve the extraction of the tape shells of capsules with a soft covering of the drum fridge in the method of manufacturing such a tape shell gelatin capsules of the present invention use a method of air cooling method instead of water cooling. Using this method of air cooling, because the tape shells of capsules not overheat and easily removed from the drum fridge, which supported the optimum temperature is approximately 21oWith, sposobnostey performance and consequently, the effective implementation of the method.

In the manufacture of capsules, soft coated in accordance with the present invention an acceptable volume flow of air in brannom the refrigerator to cool the shells of the capsules is preferably from 5 to 15 m3/min, most preferably approximately 10 m3/min.

In the manufacture of compositions according to the present invention enclosed in a capsule with a soft coating, the drug in the form of a capsule may further comprise, if necessary, pharmaceutically acceptable additives, which are usually used for such preparations in the form of capsules with soft coating. Such additives include, for example, lecithin, viscosity regulator, the odorant (e.g., peppermint oil, and so on), antioxidants (for example tocopherol, vitamin E and so on), a preservative (for example, paraben, and so on), dye, amino acids, etc.

The drug is in the form of capsules, soft coated according to the present invention can be produced by homogeneous mixing of the secondary surfactant, lubricant and surfactant, dissolving under stirring them cyclosporine and careful heating to a temperature problemleri additives, commonly used drugs in the form of capsules, soft coated, or without them in the gelatinous shell, containing as plasticizer polyethylene glycol and propylene glycol, in a machine for making capsules, soft coated using the method of air cooling.

Compositions and preparations according to the present invention are suitable under such conditions and can be applied in the same way and in the same dose range that is known compositions on the basis of cyclosporine using, if necessary, dose adjustment based on standard experiments for the study of bioavailability in animals, such as dogs or people, in particular, according to the present description.

Although the compositions of any of the excipients or components not represented specifically in the present description, they are known from the literature, see, for example, N. R. Fiedler, Lexikon der Hilfsstoffe, Edito Cantor Verlag, Aulendorf, Germany, 4th edition, 1996, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington, and The Pharmaceutical Society, London, 2nd edition, 1994, and application to the Korean patent 94-29208 filed 9.11.94.

The present invention is illustrated in more detail by the following examples. However, it is obvious that the invention is not limited to these primarly 200 - 45

Propylene carbonate - 25

Polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links - 35

Polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links - 85

The ethyllinoleate - 40

Triglyceride Caprylic/capric acid - 5

The monoglyceride of oleic acid - 35

Only 295 mg

Example 2

Component Content (mg/capsule)

Cyclosporine - 25

Polyethylene glycol 200 - 70

Polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links - 35

Polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links - 85

The ethyllinoleate - 40

Triglyceride Caprylic/capric acid - 5

The monoglyceride of oleic acid - 35

Only 295 mg

Example 3

Component Content (mg/capsule)

Cyclosporine - 25

Polyethylene glycol 200 - 100

Propylene carbonate - 50

Polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links - 35

Polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links - 85

The ethyllinoleate - 40

Triglyceride Caprylic/to the - Content (mg/capsule)

Cyclosporine - 25

Polyethylene glycol 200 - 45

Propylene carbonate - 25

Polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links - 50

Polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links - 100

The ethyllinoleate - 40

Triglyceride Caprylic/capric acid - 5

The monoglyceride of oleic acid - 35

Just - 325 mg

Example 5

Component Content (mg/capsule)

Cyclosporine - 25

Polyethylene glycol 200 - 45

Propylene carbonate - 25

Polyoxyethylene gidrirovannoe castor oil containing 50 moles ethyleneoxide links - 35

Polyoxyethylene sorbitanoleat containing 20 moles ethyleneoxide links - 85

The ethyllinoleate - 80

Triglyceride Caprylic/capric acid - 10

The monoglyceride of oleic acid - 70

Only 375 mg

Example 6

The drug is in the form of capsules with soft coating produced on the basis of the composition of example 1 using the following composition for the shell of the capsule, and then visually observed for changes in properties and States content as a result of penetration of glycerol.

As can be seen from the results shown in table 1, the product in the form of capsules, manufactured using the composition 6.1 (control group), containing as plasticizer glycerol, has some disadvantages, including the sediment as a result of penetration of glycerol, while the drug is in the form of capsules, manufactured using the composition 6.2 (experimental group), containing as plasticizer polyethylene glycol and propylene glycol, maintains a stable condition.

Example 7

The drug is in the form of capsules, soft coated, containing the composition of example 1 was obtained using the composition for shell capsules, as specified above in section 6.2 (experimental group) of example 6, using respectively the method of water cooling (water temperature approximately 12oC) and method of air cooling volume flow of air is approximately 10 m3/min).

Each case was evaluated and compared in table 2.

As can be seen from the results shown in table 2 above, the drug in the form of capsules with soft coating, obtained by the method of air cooling in accordance with the present invention has significantly better extraction of drum fridge compared with those obtained using the method of water cooling. In particular, it is generally considered that if the angle required to eject the tape gelatin shells of the drum fridge, approximately 70oor higher, then the extraction is bad, and if the angle required to eject the tape shells of the drum of the refrigerator is less than approximately 70othe extraction is good. The drug is in the form of capsules, soft coated, obtained using the method of water cooling, the poor were extracted from the drum of the refrigerator even when the tape was removed at an angle 100oor more.

In contrast, in the preparation of capsules with soft coating, obtained by the method of air cooling in accordance with the present invention, can be easily removed from the drum Kholodilin is tawania and high performance.

Example 8

The bioavailability of the drug obtained by encapsulation of the composition of example 1 in the gelatinous shell, having specified in section 6.2 of example 6 (experimental group) composition, compared with the biological availability of commercially available containing ethanol product SANDIMMUN Capsule, which was used as a control drug to assess the impact of the drug on the basis of cyclosporine in the present invention the bioavailability of cyclosporine and to change this parameter in different patients.

In this experiment, as an experienced drug and the control drug was administered at the rate of 300 mg of cyclosporine per kg weight of the rabbit.

Rabbits were kept for 4 days or more in the same conditions in wire cages on the same stern, composed of solid nutritional composition for rabbits. For experiments on oral drug rabbits were fixed for 48 hours in limiting the movement of the cage made of steel, and during this period of time, the rabbits had free access to water.

The nasogastric tube with a diameter of 5 mm, the surface of which has been pre-lubricated with vaseline to reduce friction is by Amosu 50 ml of water and then introduced into the syringe, attached to notogastral probe. The ear vein of the rabbit has expanded with the help of xylene and then took blood samples from each vein of the rabbit to experience and through 0,5, 1, 1,5, 2, 3, 4, 6, 10 and 24 hours using a disposable syringe treated with heparin. To 1 ml of the thus obtained blood was added 0.5 ml of aqueous saturated solution of sodium chloride and 2 ml of a simple ester, and then the mixture was shaken for 5 minutes and centrifuged at 5000 rpm for 10 minutes to separate supernatant (ether layer). Selected 1 ml of supernatant and subjected to treatment using activated silica on sep-pak(firm Waters). Processed sep-pak was washed in 5 ml of n-hexane and suirable 2 ml of methanol. The eluate was evaporated to dryness in a nitrogen atmosphere under reduced pressure. The residue was analyzed using GHUR (liquid chromatography high resolution) [conditions GHUR: column type-BondapakC18(firm Waters), mobile phase CH3CN:Meon:H2About in the ratio of 55:15:30, detection at 210 nm, flow rate 1.0 ml/min, column temperature 70oWith a sensitivity of 0.01 Aufs., the amount of injection of 100 ál].

The results obtained using the experimental drug and the control preliecenie values ACC andmaxthat about 4 times or more and about 7 times or more greater than those for control of the drug. Thus, we can conclude that the biological availability of the experimental drug is significantly higher than that of the control drug. In addition, an experienced drug of the present invention is characterized by the ability to reduce the difference between the respective indicators (CV %) for experimental animals. For example, the difference values of CPD is reduced about 2 times or more, and the difference values WITHmaxdecreases approximately 1.5 times compared to the control drug.

Consequently, the use of the drug in the form of capsules, soft coated in accordance with the present invention, which is administered by oral, bioavailability of cyclosporine increased approximately 4-fold compared with the known product containing ethanol, SANDIMMUNCapsule, and also reduces the difference between the bioavailability of cyclosporine for different individuals and at the same time remains stable without any changes for a long period of storage. Thus, it is obvious that the preparation of di known in the field of drugs on the basis of cyclosporine in the form of capsules with a soft covering.

Example 9

Make preparations in the form of capsules, soft gel coating, the content of which is presented in table 4.

1. The drug is in the form of gelatin capsules, soft coated, containing pharmaceutical composition, which includes

(I) a cyclosporin as active ingredient,

(II) propylene carbonate,

(III) a mixture of triglycerides of fatty acids with medium chain length and monoglyceride fatty acids as lubricant and

(IV) surface-active substance is hydrophilic-lipophilic balance (LB) which ranges from 8 to 17, preferably polyoxyethylene product is hydrogenated vegetable oil.

2. The drug under item 1, where ciclosporin is the cyclosporin A.

3. The drug according to any one of the preceding paragraphs, where the mass ratio of component (II) : ciclosporin is 1-5:1.

4. The drug according to any one of the preceding paragraphs, where the triglyceride fatty acids with medium chain length is a triglyceride Caprylic/capric acid.

5. The drug according to any one of the preceding paragraphs, where the monoglyceride of a fatty acid is a monoglyceride of oleic acid.

6. Oh acid and primary alcohol.

7. The drug under item 6, where the esterified compound of fatty acid and primary alcohol is a ethyllinoleate.

8. The drug according to any one of the preceding paragraphs, where the mass ratio sizing : cyclosporine is 2-6:1.

9. The drug PCP.6, 7, or 8, wherein the mass ratio of the monoglyceride of fatty acid-esterified compound of fatty acid and primary alcohol : triglyceride fatty acids with medium chain length is from 1: 0.1 to 3,0:0,1-3,0.

10. The drug according to any one of the preceding paragraphs, containing a mixture of polyoxyethylene product hydrogenated vegetable oil with polyoxyethylene air anhydromannitol and fatty acids.

11. The drug according to any one of the preceding paragraphs, where the mass ratio of surfactant : cyclosporine is 2-8:1.

12. The drug under item 10 or 11, where the surfactant is a mixture of surfactants consisting of polyoxyethylene hydrogenated castor oil containing 50 moles ethyleneoxide links, and polyoxyethylene of sorbitanoleat containing 20 moles ethyleneoxide links mass zootoxin the UNT(II) : sizing : surfactant is 1:0,5-8:2-6:2-8.

14. The drug according to any one of the preceding paragraphs, where a gelatin capsule with a soft coating comprises a plasticizer mixture of polyethylene glycol with propylene glycol.

15. The drug under item 14, where the mass ratio of the mixture of polyethylene glycol and propylene glycol : gelatin is 0.2 to 0.3:1.

16. The drug under item 14 or 15, where the mass ratio of polyethylene glycol : propylene glycol in the plasticizer is 1:3-6.

Priority points:

19.06.1996 on PP.1-13,15-17;

14.03.1997 on PP.6 and 7.

 

Same patents:

The invention relates to medicine, in particular for therapy and for the treatment of pathological conditions in which it participates, including an excess of bradykinin

The invention relates to medicine, namely to infectious diseases, in particular to the treatment of hemorrhagic fever with renal syndrome (HFRS)

The invention relates to new derivatives of 2-renominate General formula (I), where R1and R2represent hydrogen, C1-C6-alkyl, deformity, trifluoromethyl, C3-C6-cycloalkyl, saturated 5-membered heterocycle containing one oxygen atom, indanyl, 6,7-dihydro-5H-cyclopentadienyl or1-C6-alkyl, substituted phenyl, indayla or3-C6-cycloalkyl, R3is hydrogen, R4represents hydrogen, halogen, C1-C6-alkyl, trifluoromethyl, or R4represents a radical of the formula-O-R7where R7is hydrogen, R5represents hydrogen or R4and R5taken together may form a bivalent radical of formula-CH2-CH2-O-CH2-CH2-, R6represents hydrogen or C1-C6-alkyl, -a-b - represents a bivalent radical of the formula- (CR10= CR11or СНR10-СНR11where each R10and R11independently represents hydrogen or C1-C6-alkyl, L represents hydrogen, C1-C6-alkyl, C1-C6-allyloxycarbonyl,1-C6-alkyl, substituted by one or two penilai

The invention relates to medicine, in particular to the field of pharmacology, medicinal substances used for the prevention and treatment of diseases, the mechanisms of pathogenesis are the primary biochemical links are release from the depot of histamine and/or hyperactivation of free radical process

The invention relates to medicine, in particular for experimental Oncology, and for the treatment of malignant tumors

The invention relates to medicine, namely to obtain drugs used for the treatment of primary and secondary immunodeficiencies
The invention relates to medicine, in particular to Allergology, to methods for treating allergies

The invention relates to a new compound - derived 4-oxo-1,4-dihydropyrimidin formula I, having antihypoxic, cerebroprotective and immunotropic activity, and may find application in medicine

The invention relates to medicine and relates to drugs to prevent transplant rejection, monoclonal antibodies to the CD3 antigen of T-lymphocytes person, hybridoma producing these antibodies, and treatment of patients with reaction acute transplant rejection after kidney transplantation
The invention relates to medicine, in particular to immunology
The invention relates to medicine, specifically to medicines, analgesic action

The invention relates to compositions intended for parenteral or oral administration

The invention relates to the field of pharmaceutical industry
The invention relates to medicine and concerns capsules (tablets) with radon
The invention relates to medicine, specifically to medicines antidiarrheal action
The invention relates to pharmacy and medicine and relates to dosage forms nootropic agents
Up!